Colleen Delaney, M.D., M.Sc.

Scientific Founder and Chief Medical Officer of Nohla Therapeutics, Inc., a cellular therapy company focused on the development of universal donor cell therapies for patients with hematologic malignances and other critical diseases. Dr. Delaney is also a Member and the Madeline Dabney Adams Endowed Chair in AML Research of the Fred Hutchinson Cancer Research Center Clinical Research Division, and she established and directs the Cord Blood Transplant Program at Fred Hutch/Seattle Cancer Care Alliance. She is a Professor at the University of Washington in the Department of Pediatrics, Division of Pediatric Hematology/Oncology.